Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menopause Clear all
Completed Not applicable Interventional

Vaginal Care System for Menopausal Women With Urinary Tract Infections

NCT05573334
View directory record Official record
Conditions
Urinary Tract Infections, Vaginal Flora Imbalance
Interventions
BioNourish
Device
Lead sponsor
Vaginal Biome Science
Other
Eligibility
Up to 89 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Phase 4 Interventional

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
View directory record Official record
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brown Adipose Tissue Activity in Pre- and Postmenopausal Women

NCT02927392
View directory record Official record
Conditions
Menopause, Obesity
Interventions
Leuprolide acetate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Womens Study to Alleviate Vasomotor Symptoms

NCT04587154
View directory record Official record
Conditions
Hot Flashes
Interventions
low-fat vegan diet with 1/2 cup soybeans daily
Other
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 8, 2026, 4:33 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

NCT00880009
View directory record Official record
Conditions
Breast Cancer
Interventions
Bosutinib, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Whittier, California • Joliet, Illinois • Niles, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

NCT00454805
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
AZD2171, Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
6
States / cities
Burbank, California • Los Angeles, California • Palm Springs, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Sep 8, 2026, 4:33 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Bioidentical 'Natural' Hormone Evaluation in Early Menopause

NCT00302731
View directory record Official record
Conditions
Menopause
Interventions
Estradiol , estriol , progesterone, estradiol, progesterone, estriol, progesterone, equine estrogens m-progesteroneacetate
Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women

NCT05813067
View directory record Official record
Conditions
Vasomotor Symptoms, Postmenopausal Disorders
Interventions
JDS-HF 3.0, Placebo
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Lake Worth, Florida • Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 8, 2026, 4:33 PM EDT
Not yet recruiting Phase 2 Interventional

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

NCT07499999
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions
Exemestane, Tamoxifen
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132
View directory record Official record
Conditions
Menopause, Osteoporosis
Interventions
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
143
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

Research Investigation of Soy and Estrogen

NCT00997893
View directory record Official record
Conditions
Menopause, Hot Flashes
Interventions
Soy Phytoestrogen, Estradiol, Medroxyprogesterone Acetate (MPA), Soy Placebo, MPA Placebo
Dietary Supplement · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Not applicable Interventional Results available

Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness

NCT03150407
View directory record Official record
Conditions
Menopause Related Conditions, Postmenopausal Symptoms
Interventions
VR101 Device (Efficacy), Sham Control Ring, VR101 Device (Safety)
Device · Other
Lead sponsor
J3 Bioscience, Inc.
Industry
Eligibility
35 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Meridian, Idaho • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Raising Insulin Sensitivity in Post Menopause

NCT02274571
View directory record Official record
Conditions
Menopause
Interventions
TSEC (Tissue-selective estrogen complexes), Placebo
Drug · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
50 Years to 60 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor

NCT01778985
View directory record Official record
Conditions
Pelvic Organ Prolapse, Menopause
Interventions
Premarin, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 8, 2026, 4:33 PM EDT
Recruiting Phase 4 Interventional

Menopausal HT for Women Living With HIV (HoT)

NCT06856174
View directory record Official record
Conditions
HIV Infection, Menopause
Interventions
Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 60 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Race, Menopause and Metabolism After Exercise and Diet

NCT00882141
View directory record Official record
Conditions
Obesity, Insulin Resistance, Sedentary Lifestyle
Interventions
Diet modification, Aerobic exercise
Behavioral
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
45 Years to 80 Years · Female only
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 8, 2026, 4:33 PM EDT
Terminated Not applicable Interventional

The Effects of Lateralized Thermal Sleepwear on Sleep, Skin Temperature and Skin Moisture in Menopausal Women

NCT03037554
View directory record Official record
Conditions
Menopause Related Conditions
Interventions
Sleepwear with Lateralized Thermal Characteristics, Sham-Lateralized Sleepwear
Device
Lead sponsor
St. Peter's Hospital, Albany, NY
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 8, 2026, 4:33 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Role of Estrogen in Adipocyte Remodeling Following Surgical Menopause

NCT03631680
View directory record Official record
Conditions
Menopause Surgical, Estrogen Deficiency, Adiposity
Interventions
Bilateral Oophorectomy Surgery
Procedure
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

NCT00361569
View directory record Official record
Conditions
Menopause
Interventions
DR-2041a, DR-2041b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mindfulness Based Stress Reduction for Hot Flashes

NCT00317304
View directory record Official record
Conditions
Hot Flashes, Stress
Interventions
Mindfulness-based stress reduction
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 8, 2026, 4:33 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Dietary Fiber on Insulin Sensitivity

NCT01521806
View directory record Official record
Conditions
Focus of the Study is Insulin Sensitivity
Interventions
Dietary Fiber
Dietary Supplement
Lead sponsor
Ingredion Incorporated
Industry
Eligibility
19 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Sep 8, 2026, 4:33 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

NCT07042516
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Asimadoline
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
40 Years to 62 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 8, 2026, 4:33 PM EDT
Completed Phase 4 Interventional Results available

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

NCT00688909
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older · Female only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
48
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Grass Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 8, 2026, 4:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Hydration & Female Life Stages

NCT07653620
View directory record Official record
Conditions
Dehydration, Menstruation, Pre-menopause, Peri-menopausal Women, Post-menopausal Women, Hydration
Interventions
placebo beverage, electrolyte beverage
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Bradenton, Florida • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 8, 2026, 4:33 PM EDT